Atorvastatin formulation
Pro Research Analysisby 
Searched over 200M research papers for "atorvastatin formulation"
Atorvastatin Formulation: Solid Forms, Excipients, and Manufacturing Considerations
Formulating atorvastatin, especially in its calcium trihydrate form, requires careful attention to solid-state properties and compatibility with excipients. The transformation between hydrate and anhydrate forms during manufacturing can impact the drug’s physicochemical and mechanical properties, potentially leading to product quality issues. Studies have shown that atorvastatin calcium trihydrate (ACT) can be successfully formulated into tablets using excipients like microcrystalline cellulose, calcium carbonate, lactose monohydrate, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, and polysorbate 80. These formulations maintained acceptable quality parameters such as weight variation, hardness, disintegration, and dissolution, with no significant incompatibility between ACT and the excipients, except for a minor physical interaction with microcrystalline cellulose that did not affect performance. The manufacturing process can induce partial amorphization, but the final product still meets pharmacopeia standards .
Enhancing Solubility and Dissolution: Supersaturated Gels, Solid Dispersions, and Co-Amorphous Systems
Atorvastatin’s poor aqueous solubility, especially at acidic pH, limits its bioavailability. Innovative formulation strategies have been developed to address this challenge. Supersaturated gel formulations (SGF) using PEG 200 and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) as solubilizer and precipitation inhibitor, respectively, have shown a 15-fold increase in solubility at gastric pH and over 95% dissolution within 2 hours, outperforming commercial products. These gels also demonstrated physical stability for at least 100 days .
Solid dispersions with amphiphilic carriers like Pluronic F127 and F68 have also been effective, increasing atorvastatin’s solubility and dissolution rate, with up to 93% of the drug dissolved within 30 minutes. These formulations significantly improved in vivo absorption compared to standard tablets . Additionally, co-amorphous systems using lisinopril as a co-former have been shown to enhance atorvastatin’s dissolution and maintain supersaturation, further improving its solubility profile .
Nanotechnology Approaches: Nanoparticles, Nanospheres, and Lipid Carriers
Nanotechnology-based formulations have been widely explored to improve atorvastatin’s oral bioavailability and therapeutic efficacy. Zein-based nanospheres and chitosan nanoparticles have demonstrated enhanced drug loading, encapsulation efficiency, and dissolution rates. For example, zein nanospheres increased oral bioavailability threefold compared to commercial tablets, while chitosan nanoparticles in mouth-dissolving tablets achieved rapid dissolution and potentially bypassed first-pass metabolism 34.
Nanostructured lipid carriers (NLCs) have also shown promise, with high encapsulation efficiency and a 3.6-fold increase in bioavailability over suspensions. These carriers not only improved pharmacokinetic parameters but also provided better lipid-lowering effects and reduced hepatic side effects in animal models .
Alternative Delivery Routes: Transdermal and Intra-Articular Formulations
To overcome oral delivery limitations and reduce systemic side effects, alternative routes have been investigated. Transdermal ultra-flexible vesicles (transfersomes) loaded with atorvastatin calcium achieved significant improvements in bioavailability (up to 13.3-fold over traditional gels) and maintained antihyperlipidemic activity without increasing liver toxicity. These vesicles also provided sustained drug release and better skin permeation .
For localized therapy, such as in osteoarthritis, intra-articular delivery systems using lecithin-coated zein nanoparticles in thermogels have been developed. These systems provided sustained release, effective drug deposition in joints, and significant anti-inflammatory effects in animal models .
Specialized Formulations: Micelles for Blood-Brain Barrier Penetration
Micellar formulations of atorvastatin have been explored for targeting brain tumors like glioblastoma. These micelles enabled higher serum concentrations and showed greater cytotoxicity against tumor cells in 3D models compared to free drug, suggesting potential for intravenous administration in cancer therapy .
Conclusion
A wide range of formulation strategies have been developed to address atorvastatin’s solubility, stability, and bioavailability challenges. These include solid-state optimization, supersaturated gels, solid dispersions, co-amorphous systems, nanotechnology-based carriers, and alternative delivery routes such as transdermal and intra-articular systems. Collectively, these approaches have demonstrated significant improvements in dissolution, absorption, and therapeutic efficacy, offering promising alternatives to conventional atorvastatin formulations for various clinical applications 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic